Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia

Journal of Clinical Pharmacology

Volumn 51, Issue 9, 2011, Pages 1264-1275

  Hassan, Hazem E ^a,b   Othman, Ahmed A ^a,c,g   Eddington, Natalie D ^a   Duffy, Lynn ^d   Xiao, Li ^d   Waites, Ken B ^d   Kaufman, David A ^e   Fairchild, Karen D ^e   Terrin, Michael L ^f   Viscardi, Rose M ^f  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Ein Helwan   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

Azithromycin; bronchopulmonary dysplasia; pharmacokinetics; prematurity; Ureaplasma

Indexed keywords

AZITHROMYCIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL COLONIZATION; BODY WEIGHT; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVITY; FEMALE; GESTATIONAL AGE; HUMAN; INFECTION RISK; LUNG DYSPLASIA; MALE; NEWBORN; PHARMACOKINETICS; PREMATURITY; SINGLE DRUG DOSE; TREATMENT OUTCOME; UREAPLASMA INFECTION;

AZITHROMYCIN; BRONCHOPULMONARY DYSPLASIA; FEMALE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; RESPIRATION, ARTIFICIAL; UREAPLASMA; UREAPLASMA INFECTIONS;

EID: 80051736595     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010382021     Document Type: Article

References (59)

1. Wang EL, Ohlsson A, Kellner JD. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr. 1995 ; 127: 640-644
2. Castro-Alcaraz S, Greenberg EM, Bateman DA, Regan JA. Patterns of colonization with Ureaplasma urealyticum during neonatal intensive care unit hospitalizations of very low birth weight infants and the development of chronic lung disease. Pediatrics. 2002 ; 110: E45 - E45
3. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005 ; 18: 757-789 (Pubitemid 41504514)
4. Katz B, Patel P, Duffy L, et al. Characterization of ureaplasmas isolated from preterm infants with and without bronchopulmonary dysplasia. J Clin Microbiol. 2005 ; 43: 4852-4854 (Pubitemid 41298293)
5. Schelonka RL, Katz B, Waites KB, Benjamin DK. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 2005 ; 24: 1033-1039 (Pubitemid 43011055)
6. Colaizy TT, Morris CD, Lapidus J, Sklar RS, Pillers DA. Detection of ureaplasma DNA in endotracheal samples is associated with bronchopulmonary dysplasia after adjustment for multiple risk factors. Pediatr Res. 2007 ; 61: 578-583 (Pubitemid 46650010)
7. Viscardi RM, Hasday JD. Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence. Pediatr Res. 2009 ; 65: 84R - 90R
8. Rudd PT, Cassell GH, Waites KB, Davis JK, Duffy LB. Ureaplasma urealyticum pneumonia: experimental production and demonstration of age-related susceptibility. Infect Immun. 1989 ; 57: 918-925 (Pubitemid 19064560)
9. Walsh WF, Butler J, Coalson J, et al. A primate model of Ureaplasma urealyticum infection in the premature infant with hyaline membrane disease. Clin Infect Dis. 1993 ; 17 (suppl 1). S158 - S162
10. Patterson AM, et al. Ureaplasma urealyticum respiratory tract colonization is associated with an increase in IL-1β and TNF-a relative to IL-6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J. 1998 ; 17: 321-328
11. Manimtim WM, Taciak V, Lovchik J, et al. Ureaplasma urealyticum modulates endotoxin-induced cytokine release by human monocytes derived from preterm and term newborns and adults. Infect Immun. 2001 ; 69: 3906-3915 (Pubitemid 32493312)
12. Viscardi RM, Manimtim WM, Sun CCJ, Duffy L, Cassell GH. Lung pathology in premature infants with Ureaplasma urealyticum infection. Pediatr Dev Pathol. 2002 ; 5: 141-150 (Pubitemid 34475446)
13. Viscardi RM, Kaplan J, Lovchik JC, et al. Characterization of a murine model of Ureaplasma urealyticum pneumonia. Infect Immun. 2002 ; 70: 5721-5729
14. Yoder BA, Coalson JJ, Winter VT, et al. Effects of antenatal colonization with Ureaplasma urealyticum on pulmonary disease in the immature baboon. Pediatr Res. 2003 ; 54: 797-807 (Pubitemid 37456542)
15. Viscardi R, Manimtim W, He JR, et al. Disordered pulmonary myofibroblast distribution and elastin expression in preterm infants with Ureaplasma urealyticum pneumonitis. Pediatr Dev Pathol. 2006 ; 9: 143-151 (Pubitemid 44049397)
16. Viscardi RM, Atamas SP, Luzina IG, et al. Antenatal Ureaplasma urealyticum respiratory tract infection stimulates proinflammatory, profibrotic responses in the preterm baboon lung. Pediatr Res. 2006 ; 60: 141-146 (Pubitemid 44297582)
17. Renaudin H, Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis. 1990 ; 9: 838-841
18. Bowman ED, Dharmalingam A, Fan WQ, Brown F, Garland SM. Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants. Pediatr Infect Dis J. 1998 ; 17: 615-620 (Pubitemid 28340873)
19. Jonsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr. 1998 ; 87: 1079-1084 (Pubitemid 28476007)
20. Baier RJ, Loggins J, Kruger TE. Failure of erythromycin to eliminate airway colonization with ureaplasma urealyticum in very low birth weight infants. BMC Pediatr. 2003 ; 3: 10
21. Rubin BK. Macrolides as biologic response modifiers. J Respir Dis. 2002 ; 23: S31 - S38
22. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000 ; 292: 156-163 (Pubitemid 30026366)
23. Tsai WC, Standiford TJ. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des. 2004 ; 10: 3081-3093 (Pubitemid 39242903)
24. Kawashima M, Yatsunami J, Fukuno Y, et al. Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung. 2002 ; 180: 73-89 (Pubitemid 35477917)
25. Beigelman A, Gunsten S, Mikols CL, et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest. 2009 ; 136: 498-506
26. Tsai WC, Rodiguez MI, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004 ; 170: 1331-1339 (Pubitemid 39657198)
27. Tsai WC, Hershenson MB, Zhou Y, Sajjan U. Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res. 2009 ; 58: 491-501
28. Girard AE, Cimochowski C, Faiella JA. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J Antimicrob Chemother. 1996 ; 37 (suppl C). 9-19 (Pubitemid 26283376)
29. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother. 1996 ; 40: 2375-2379 (Pubitemid 26328049)
30. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest. 2004 ; 125: 965-973 (Pubitemid 38367287)
31. Arnon S, Grigg J, Silverman M. Pulmonary inflammatory cells in ventilated preterm infants: effect of surfactant treatment. Arch Dis Child. 1993 ; 69: 44-48 (Pubitemid 23232981)
32. Auten RL, Ekekezie II. Blocking leukocyte influx and function to prevent chronic lung disease of prematurity. Pediatr Pulmonol. 2003 ; 35: 335-341 (Pubitemid 36529971)
33. Liao L, Ning Q, Li Y, et al. CXCR2 blockade reduces radical formation in hyperoxia-exposed newborn rat lung. Pediatr Res. 2006 ; 60: 299-303 (Pubitemid 44267742)
34. Duffy LB, Crabb D, Searcey K, Kempf MC. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother. 2000 ; 45 (suppl 1). 29-33 (Pubitemid 30195554)
35. Loza E, Martinez Beltran J, Baquero F, et al. Comparative in vitro activity of clarithromycin. Spanish Collaborative Group. Eur J Clin Microbiol Infect Dis. 1992 ; 11: 856-866
36. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007 ; 62: 483-488 (Pubitemid 47476210)
37. Jacobs RF, Maples HD, Aranda JV, et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J. 2005 ; 24: 34-39 (Pubitemid 40353314)
38. Donovan EF, Tyson JE, Ehrenkranz RA, et al. Inaccuracy of Ballard scores before 28 weeks' gestation. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1999 ; 135: 147-152
39. Pellicer A, Valverde E, Elorza MD, et al. Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial. Pediatrics. 2005 ; 115: 1501-1512 (Pubitemid 43843157)
40. Walsh MC, Yao Q, Gether P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004 ; 114: 1305-1311 (Pubitemid 41647693)
41. Barrett B, Borek-Dohalsky V, Feit P, et al. Validated HPLC-MS-MS method for determination of azithromycin in human plasma. Anal Bioanal Chem. 2005 ; 383: 210-217 (Pubitemid 41442912)
42. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng. 1982 ; 8: 195-222
43. Waites KB, Duffy LB, Schwartz S, Talkington DF Clinical Microbiology Procedure Handbook. 2 nd ed.Washington, DC: ASM Press; 2004. Isenberg H, ed. Washington, DC: ASM Press ; 2004 :
44. Novy MJ, Axthelm MK, Sadowsky DW, et al. Ureaplasma parvum or Mycoplasma hominis as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques. Reprod Sci. 2009 ; 16: 56-70
45. Blanchard A, Hentschel J, Duffy L, Baldus K, Cassell GH. Detection of Ureaplasma urealyticum by polymerase chain reaction in the urogenital tract of adults, in amniotic fluid, and in the respiratory tract of newborns. Clin Infect Dis. 1993 ; 17 (suppl 1). S148 - S153
46. Xiao L, Glass JI, Paralanov V, et al. Detection and characterization of human ureaplasma species and serovars by real-time PCR. J Clin Microbiol. 2010 ; 48: 2715-2723
47. Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005 ; 288: L1026 - L1032
48. Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 2005 ; 314: 738-744 (Pubitemid 41043857)
49. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008 ; 48: 303-332 (Pubitemid 351738156)
50. Zeitlinger M, Wagner CC, Heinisch B. Ketolides-the modern relatives of macrolides: the pharmacokinetic perspective. Clin Pharmacokinet. 2009 ; 48: 23-38
51. Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother. 1995 ; 39: 1875-1877
52. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother. 1999 ; 33: 218-228 (Pubitemid 29109685)
53. Gordon EM, Blumer L. Rationale for single and high dose treatment regimens with azithromycin. Pediatr Infect Dis J. 2004 ; 23: S102-107
54. Dunne MW, Latiolais T, Lewis B, et al. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. J Antimicrob Chemother. 2003 ; 52: 469-472 (Pubitemid 37120728)
55. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. Pediatr Infect Dis J. 2004 ; 23: S135-139
56. Cohen R, Reinert P, De La Rocque F, et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2002 ; 21: 297-303 (Pubitemid 34326867)
57. Girard D, Finegan SM, Dunne MW, Lame ME. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother. 2005 ; 56: 365-371 (Pubitemid 41158527)
58. Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of broncho-pulmonary dysplasia: a pilot study. Respir Res. 2007 ; 8: 41
59. Ballard HO, Bernard P, Whitehead V, et al. Use of azithromycin for early treatment of Ureaplasma spp. in preterm infants: a randomized, double-blind, placebo-controlled trial. EPAS2009. 2009 ; 4515: 4513